Cargando…

RASopathic Skin Eruptions during Vemurafenib Therapy

PURPOSE: Vemurafenib is a potent inhibitor of V600 mutant BRAF with significant impact on progression-free and overall survival in advanced melanoma. Cutaneous side effects are frequent. This single-center observational study investigates clinical and histological features of these class-specific cu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rinderknecht, Jeannine D., Goldinger, Simone M., Rozati, Sima, Kamarashev, Jivko, Kerl, Katrin, French, Lars E., Dummer, Reinhard, Belloni, Benedetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597638/ https://www.ncbi.nlm.nih.gov/pubmed/23516541 http://dx.doi.org/10.1371/journal.pone.0058721

Ejemplares similares

Correction: RASopathic Skin Eruptions during Vemurafenib Therapy
por: Rinderknecht, Jeannine D., et al.
Publicado: (2013)

A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma
por: Goldinger, Simone M, et al.
Publicado: (2015)

Lichenoid Drug Eruption following Intravenous Application of Orally Formulated Diamorphine, a Semisynthetic Heroin
por: Kolm, I., et al.
Publicado: (2013)

Disseminated Eruptive Blue Nevi in a Young Adult Patient
por: Maredia, Hasina, et al.
Publicado: (2020)

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
por: Krähenbühl, Lukas, et al.
Publicado: (2018)

Cervicofacial Botryomycosis: Is Atopic Dermatitis a Predisposing Factor?
por: Heppt, Markus Vincent, et al.
Publicado: (2014)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

A Report of Two Cases of Solid Facial Edema in Acne
por: Kuhn-Régnier, Sarah, et al.
Publicado: (2017)

Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome
por: Maredia, Hasina, et al.
Publicado: (2021)

Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome)
por: Mangana, Joanna, et al.
Publicado: (2017)

Sarcoid-like reactions in patients receiving modern melanoma treatment
por: Dimitriou, Florentia, et al.
Publicado: (2018)

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
por: Mangana, Joanna, et al.
Publicado: (2015)

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

Paracetamol-induced fixed drug eruption presenting as eyelid skin necrosis
por: Kimmatkaar, Prajakta, et al.
Publicado: (2018)

On Vaccinal Skin Eruptions
por: Thin, George
Publicado: (1881)

Vaccinal Skin Eruptions
Publicado: (1882)

The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
por: Dummer, Reinhard, et al.
Publicado: (2023)

Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib
por: Rajczykowski, Marcin, et al.
Publicado: (2018)

Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
por: Pham, James P., et al.
Publicado: (2023)

Heterogeneous Tumor Subpopulations Cooperate to Drive Invasion
por: Chapman, Anna, et al.
Publicado: (2014)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Itching in Syphilitic Skin Eruptions
por: Singh, Sohan, et al.
Publicado: (1941)

Diseases of the Skin and the Eruptive Fevers
Publicado: (1909)

Olanzapine-induced Skin Eruptions
por: Chawla, Nishtha, et al.
Publicado: (2017)

Diseases of the Skin and the Eruptive Fevers
Publicado: (1909)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma
por: Cheng, Phil F, et al.
Publicado: (2015)

Lupus-like skin Eruptions as Indicator of Disease Progression and Poor Outcome in Patients with Haematological Malignancies
por: KREUTER, Alexander, et al.
Publicado: (2021)

Scurvy in a patient on vemurafenib
por: Gerstenblith, Meg R., et al.
Publicado: (2014)

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

In melanoma, beta-catenin acts as suppressor of invasion through a cell-type specific mechanism
por: Arozarena, Imanol, et al.
Publicado: (2011)

M. Cazenave on Syphilitic Eruptions of the Skin
Publicado: (1847)

Olanzapine-induced reversible skin eruption
por: Deshmukh, Rohit P.
Publicado: (2023)

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma
por: Hagen, Brenda, et al.
Publicado: (2014)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Complete remission of critical neurohistiocytosis by vemurafenib
por: Euskirchen, Philipp, et al.
Publicado: (2015)

Delayed-onset vemurafenib-induced panniculitis
por: Vance, Stephen L., et al.
Publicado: (2017)

A Rare Cause of Uveitis: Vemurafenib
por: Sızmaz, Selçuk, et al.
Publicado: (2018)

XL888 limits vemurafenib-induced proliferative skin events by suppressing paradoxical MAPK activation
por: Phadke, Manali, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bqps010kmjve32uqp0jh0mjpbg